Remove 2024 Remove Diabetes Remove HIV Treatment and Prevention Agents
article thumbnail

Tranq dope (fentanyl-xylazine combination): A new horizon in opioid withdrawal treatment

ALiEM - Pharm Pearls

Bupe Allergy Buprenorphine induction has been the mainstay of emergency department treatment of opioid use disorder for more than a decade [11, 12]. Of note, screening is often required for insurance approval for substance use treatment. 2024 study [16]. Prolonged QTc was defined as >450 msec.

article thumbnail

Top 20 RNAi Therapeutic Companies Based on 2022 R&D Expenditure

PharmaShots

This drug is currently in multiple P-IIa clinical trials and is being evaluated in combination with other antiviral agents for cHBV. ARO-AAT and ARO-APOC3 are among the highest-phase products developing under Arrowhead’s pipeline for the treatment of liver diseases. R&D Expenditure: $85.1M R&D Expenditure: $437.9M